Phase II study of vindesine in patients with metastatic breast cancer

M. A. Cobleigh, S. D. Williams, L. H. Einhorn

Research output: Contribution to journalArticle

17 Scopus citations


Twenty-six patients with far-advanced, refractory breast cancer were treated iv with vindesine (DVA) at a dose of 3 mg/m2/week. In 21 evaluable patients there were six partial remissions. Four patients who did not respond after at least four doses of intermittent DVA received continuous-infusion DVA at a dose of 1.5 mg/m2/day x 2 every other week; none responded. Five of the six responders had had disease progression on other vinca alkaloids. Leukopenia and neuromuscular toxicity were dose-limiting.

Original languageEnglish (US)
Pages (from-to)659-663
Number of pages5
JournalCancer Treatment Reports
Issue number7-8
StatePublished - Jan 1 1981
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of vindesine in patients with metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this